Small Molecule Ligand for Targeted Influenza Treatment

Back to all technologies
Download as PDF
2018-LOW-68327
Researchers at Purdue University have developed a small molecule ligand (SML) which targets influenza neuraminidase, a glycoprotein that accounts for 20% of the glycoproteins in the influenza virus envelope. The SML can conjugate with drugs to promote drug entrance in influenza infected cells. Both in vitro and in vivo rat studies were performed with zanamivir-SML conjugate. Zanamivir is a neuraminidase inhibitor that prevents the influenza virus from escaping the host cell. The in vitro results with H1N1 MDCK cells showed 100-fold higher binding of zanamivir SML in comparison to zanamivir alone. Under the in vivo study conditions, it was found that 100% of the rats treated with zanamivir SML survived 15 days in comparison to 60% survival rate with zanamivir alone.

Advantages:
-Reduced side effects of flu therapy
-Site specific drug delivery
-Improved drug efficacy

Potential Applications:
-Drug design
-Influenza therapy
-Pharmaceuticals
Sep 27, 2021
Foreign-Patent
Hong Kong
(None)
(None)

Jan 26, 2021
NATL-Patent
United States
(None)
(None)

Jul 20, 2019
PCT-Patent
WO
(None)
(None)

Jul 20, 2019
NATL-Patent
Canada
(None)
(None)

Jul 20, 2019
NATL-Patent
China
(None)
(None)

Jul 20, 2019
NATL-Patent
European Patent
(None)
(None)

Jul 20, 2019
NATL-Patent
Japan
(None)
(None)

Jul 19, 2019
NATL-Patent
Australia
(None)
(None)

May 10, 2019
Provisional-Patent
United States
(None)
(None)

Jul 26, 2018
Provisional-Patent
United States
(None)
(None)

(None)
Foreign-Patent
Hong Kong
(None)
(None)
Purdue Office of Technology Commercialization
The Convergence Center
101 Foundry Drive, Suite 2500
West Lafayette, IN 47906

Phone: (765) 588-3475
Fax: (765) 463-3486
Email: otcip@prf.org